XIAP and triple-negative breast carcinoma: It decreases the tumorigenic potential of gefitinib-resistant non-small cell lung cancer cells (Cao et al., 2015), inhibits infiltration of mast tumor cells harboring imatinib-resistant D814Y KIT proto-oncogene (Jin et al., 2010), and proliferation of triple-negative breast cancer cells by decreasing the expression levels of B cell lymphoma-2 (Bcl-2), survivin, and X-linked inhibitor of apoptosis protein (XIAP) (Yakhni et al., 2019).